Equities

PTC Therapeutics Inc

PTC Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)43.23
  • Today's Change0.34 / 0.79%
  • Shares traded548.74k
  • 1 Year change+99.95%
  • Beta0.6183
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments877411773
Total Receivables, Net161156110
Total Inventory312216
Prepaid expenses15010655
Other current assets, total------
Total current assets1,219694954
Property, plant & equipment, net179175130
Goodwill, net828282
Intangibles, net379706725
Long term investments------
Note receivable - long term------
Other long term assets203239
Total assets1,8961,7061,938
LIABILITIES
Accounts payable6.052723
Accrued expenses116126106
Notes payable/short-term debt000
Current portion long-term debt/capital leases19775212
Other current liabilities, total206114107
Total current liabilities603406509
Total long term debt1,9211,276977
Total debt2,1181,3511,188
Deferred income tax56103137
Minority interest------
Other liabilities, total134268314
Total liabilities2,7142,0531,937
SHAREHOLDERS EQUITY
Common stock0.080.070.07
Additional paid-in capital2,4662,3052,124
Retained earnings (accumulated deficit)(3284)(2657)(2098)
Treasury stock - common------
Unrealized gain (loss)0.33(0.49)(0.6)
Other equity, total(1.61)5.29(24)
Total equity(819)(347)1.44
Total liabilities & shareholders' equity1,8961,7061,938
Total common shares outstanding767371
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.